Curated News
By: NewsRamp Editorial Staff
May 28, 2025
TransCode Therapeutics Names Dr. Phillip D. Zamore to Scientific Advisory Board
TLDR
- Dr. Zamore's appointment enhances TransCode's RNA-targeted cancer therapy programs, giving a strategic edge in the field.
- TransCode focuses on treating metastatic disease through intelligent RNA therapeutics delivery with TTX nanoparticle platform.
- TransCode's innovative RNA therapeutics offer hope for better cancer treatment by targeting specific genetic markers of metastatic tumors.
- Dr. Zamore's foundational work in RNA biology adds a fascinating dimension to TransCode's cutting-edge cancer therapy research.
Impact - Why it Matters
This news highlights the strategic addition of a renowned expert in RNA research to TransCode's team, signaling a significant step forward in the development of RNA-targeted cancer therapies. Dr. Zamore's appointment underscores the company's commitment to advancing innovative treatments for metastatic disease.
Summary
TransCode Therapeutics (NASDAQ: RNAZ) appoints Dr. Phillip D. Zamore, a prominent figure in RNA research, to its Scientific Advisory Board. Dr. Zamore brings expertise in RNA biology and gene silencing mechanisms, enhancing the company's RNA-targeted cancer therapy programs. TransCode focuses on treating metastatic disease with its lead candidate, TTX-MC138.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, TransCode Therapeutics Names Dr. Phillip D. Zamore to Scientific Advisory Board
